Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on ...

In March 2024, the US Food and Drug Administration (FDA) granted accelerated approval to Rezdiffra™ (resmetirom) in conjunction with diet and exercise for the treatment of adults with ...

but US biotech Madrigal Pharma thinks it now has enough evidence for its drug resmetirom to support regulatory filings. The Massachusetts company has reported the results of the phase 3 MAESTRO ...

Madrigal Pharmaceuticals MDGL currently markets Rezdiffra (resmetirom), as the first and only FDA-approved therapy for the treatment of adult patients with noncirrhotic MASH with moderate to ...

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Rezdiffra (resmetirom), a once-daily, oral and liver-directed THR-β agonist. Rezdiffra gained the FDA’s accelerated approval in March 2024 for adult patients with nonalcoholic steatohepatitis ...

In March 2024, the US Food and Drug Administration (FDA) granted accelerated approval to Rezdiffra™ (resmetirom) in conjunction with diet and exercise for the treatment of adults with noncirrhotic ...

Analysts have suggested that the benefit of semaglutide is similar to that seen with Madrigal Pharma's Rezdiffra (resmetirom), currently the only FDA-approved therapy for MASH, which is also known ...

French biotech Inventiva’s layoffs and pipeline shift are expected to help keep the company operational into the second half of 2026.

Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...

Rezdiffra (resmetirom) is an FDA-approved oral medication indicated for adults with noncirrhotic non-alcoholic steatohepatitis (NASH) and moderate to advanced liver fibrosis. As a thyroid hormone ...